deferoxamine has been researched along with Diabetic Nephropathies in 6 studies
Deferoxamine: Natural product isolated from Streptomyces pilosus. It forms iron complexes and is used as a chelating agent, particularly in the mesylate form.
desferrioxamine B : An acyclic desferrioxamine that is butanedioic acid in which one of the carboxy groups undergoes formal condensation with the primary amino group of N-(5-aminopentyl)-N-hydroxyacetamide and the second carboxy group undergoes formal condensation with the hydroxyamino group of N(1)-(5-aminopentyl)-N(1)-hydroxy-N(4)-[5-(hydroxyamino)pentyl]butanediamide. It is a siderophore native to Streptomyces pilosus biosynthesised by the DesABCD enzyme cluster as a high affinity Fe(III) chelator.
Diabetic Nephropathies: KIDNEY injuries associated with diabetes mellitus and affecting KIDNEY GLOMERULUS; ARTERIOLES; KIDNEY TUBULES; and the interstitium. Clinical signs include persistent PROTEINURIA, from microalbuminuria progressing to ALBUMINURIA of greater than 300 mg/24 h, leading to reduced GLOMERULAR FILTRATION RATE and END-STAGE RENAL DISEASE.
| Excerpt | Relevance | Reference |
|---|---|---|
| " These results indicate that in uremic diabetic patients with lower intake of Al containing drugs, an early accumulation of Al in the whole body occurs possibly because of the enhanced absorption rate of Al at an intestine and/or the low PTH level." | 1.28 | [High deposition rate of aluminum in tissues in diabetic hemodialysis patients]. ( Chimata, M; Ideura, T; Iwasaki, S; Kawamura, M; Koshikawa, S; Sudo, M; Yoshimura, A, 1990) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (33.33) | 18.7374 |
| 1990's | 2 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Ozkan, S | 1 |
| Isildar, B | 1 |
| Ercin, M | 1 |
| Gezginci-Oktayoglu, S | 1 |
| Konukoglu, D | 1 |
| Neşetoğlu, N | 1 |
| Oncul, M | 1 |
| Koyuturk, M | 1 |
| Feng, Y | 1 |
| Jia, L | 1 |
| Ma, W | 1 |
| Tian, C | 1 |
| Du, H | 1 |
| Whiting, PH | 1 |
| Jiffri, E | 1 |
| Thomson, L | 1 |
| Beaton, W | 1 |
| Williamson, FW | 1 |
| Long, WF | 1 |
| Iwasaki, S | 1 |
| Ideura, T | 1 |
| Yoshimura, A | 1 |
| Chimata, M | 1 |
| Kawamura, M | 1 |
| Sudo, M | 1 |
| Koshikawa, S | 1 |
| Felsenfeld, AJ | 1 |
| Rodriguez, M | 1 |
| Coleman, M | 1 |
| Ross, D | 1 |
| Llach, F | 1 |
| Andress, DL | 1 |
| Kopp, JB | 1 |
| Maloney, NA | 1 |
| Coburn, JW | 1 |
| Sherrard, DJ | 1 |
6 other studies available for deferoxamine and Diabetic Nephropathies
| Article | Year |
|---|---|
Therapeutic potential of conditioned medium obtained from deferoxamine preconditioned umbilical cord mesenchymal stem cells on diabetic nephropathy model.
Topics: Animals; Creatinine; Culture Media, Conditioned; Deferoxamine; Diabetes Mellitus; Diabetic Nephropat | 2022 |
Iron Chelator Deferoxamine Alleviates Progression of Diabetic Nephropathy by Relieving Inflammation and Fibrosis in Rats.
Topics: Animals; Deferoxamine; Diabetes Mellitus; Diabetic Nephropathies; Fibrosis; Inflammation; Iron; Iron | 2023 |
The effect of desferrioxamine on the development of renal dysfunction in streptozotocin-induced diabetes.
Topics: Animals; Blood Glucose; Creatinine; Deferoxamine; Diabetes Mellitus, Experimental; Diabetic Nephropa | 1997 |
[High deposition rate of aluminum in tissues in diabetic hemodialysis patients].
Topics: Adult; Aged; Aluminum; Deferoxamine; Diabetic Nephropathies; Female; Glomerulonephritis; Humans; Mal | 1990 |
Desferrioxamine therapy in hemodialysis patients with aluminum-associated bone disease.
Topics: Aluminum; Bone and Bones; Bone Diseases; Calcium; Deferoxamine; Diabetic Nephropathies; Female; Huma | 1989 |
Early deposition of aluminum in bone in diabetic patients on hemodialysis.
Topics: Aluminum; Bone and Bones; Bone Development; Deferoxamine; Diabetes Mellitus, Type 1; Diabetic Nephro | 1987 |